Innatus Therapeutics (Shanghai) Co. Ltd. has synthesized integrin β2 regulators reported to be useful for the treatment of alopecia areata, gouty arthritis, autoimmune hepatitis, inflammatory bowel disease, peritonitis, rheumatoid arthritis, Sjögren’s disease and systemic lupus erythematosus, among others.
Innovent Biologics Co. Ltd. presented data for IBI-3034, a chimeric Fc fusion protein comprising transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen (BCMA) for the treatment of autoimmune diseases.
Kali Therapeutics Inc. has developed a novel T-cell engager (TCE) bispecific antibody, KT-502, targeting CD19 and CD3 for the treatment of autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has disclosed discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus and rheumatoid arthritis.
Hinge Bio Inc. has obtained IND approval from the FDA to initiate a phase I study of HB-2198 in patients with the B cell-mediated autoimmune diseases systemic lupus erythematosus (SLE) and lupus nephritis. The trial is expected to open this quarter.
Kyorin Pharmaceutical Co. Ltd. is licensing Hinge Bio Inc.’s multispecific antibody-based therapy HB-2198 in Japan for multiple autoimmune indications, starting with systemic lupus erythematosus.
Arcus Biosciences Inc. has announced five new research programs for autoimmune and inflammatory diseases, and is targeting initiation of the first clinical studies next year.
Kyorin Pharmaceutical Co. Ltd. is licensing Hinge Bio Inc.’s multispecific antibody-based therapy HB-2198 in Japan for multiple autoimmune indications, starting with systemic lupus erythematosus.
